title: Treatment of oropharyngeal cancer in renal transplant recipients without cessation of immunosuppressive therapy.
abstract: BACKGROUND
  Renal transplantation and immunosuppression are associated with an increased incidence of malignancy. Reduction or cessation of immunosuppressive therapy has been advocated in these cases to prevent tumor progression and recurrence. We evaluated the outcome of treatment of oropharyngeal cancer (OC) after renal transplantation without cessation of immunosuppressive therapy.
  
  
  METHODS
  The database of patients with OC after renal transplantation was analyzed with respect to age, sex, type of immunosuppression, interval between transplantation and diagnosis of cancer, as well as method of treatment and survival.
  
  
  RESULTS
  Thirty one (2.06%) renal transplant recipients developed malignancy including 6 (20%) with OC. Lingual cancer was seen in three, and one each showed an isolated tonsillar lymphoma, a parotid carcinoma, or a carcinoma of the larynx with only the last having had two other malignancies in the past. Three subjects were on immunosuppression with azathioprine and prednisolone, and the others were prescribed cyclosporine and prednisolone. Average time from transplantation to diagnosis of OC was 106 months. The interval was the shortest (2 years) for tonsillar lymphoma in an 18-year-old patient who received cyclosporine and showed features of left follicular tonsillitis. The patient with advanced carcinoma of the larynx did not receive any treatment and succumbed within 3 months. The dose of cyclosporine was reduced in the lymphoma case but immunosuppression was not altered in the other patients. All subjects were treated with a standard protocol. During a mean follow-up of 33 months, one had local recurrence of parotid carcinoma and the others showed well functioning renal grafts.
  
  
  CONCLUSIONS
  Comprehensive treatment of OC after renal transplantation without withdrawing the immunosuppression prolonged the life of these patients with functioning grafts.
authors.affiliation: Department of Urology, Postgraduate Institute of Medical Education and Research, #202-A, Sector 24-A, Chandigarh 160023, India. shrawanksingh2002@yahoo.com
authors.forename: S K
authors.initials: SK
authors.lastname: Singh
authors.forename: A K
authors.initials: AK
authors.lastname: Gupta
authors.forename: V
authors.initials: V
authors.lastname: Jha
authors.forename: H S
authors.initials: HS
authors.lastname: Kohli
authors.forename: K L
authors.initials: KL
authors.lastname: Gupta
authors.forename: M
authors.initials: M
authors.lastname: Minz
authors.forename: V
authors.initials: V
authors.lastname: Sakhuja
mesh_terms: D000293:Adolescent; D000328:Adult; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D009959:Oropharyngeal Neoplasms / Q000628:therapy*; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents